D’Sylva appointed MD at Mimitopes

FORMER director of research and development at Murdoch University, Paul D’Sylva, has joined PharmAust Limited as managing director (executive capacity) of the company’s wholly owned subsidiary, Mimitopes Pty Ltd. Dr D’Sylva will start his new position on July 1 and will focus on delivering earnings growth and expanding into new markets. Acquired by PharmAust in March, Mimotopes’ cornerstone technology is its patented SynPhase, which allows for the fast production of large numbers of compounds that can be applied in areas such as immunology. Mimotopes’ clients include Pfizer, Infinity Pharmaceuticals and Phylogica. While at Murdoch University, Dr D’Sylva led the development of several research and commericalisation joint ventures, including the establishment of the $12.5 million technology investment fund, Murdoch Westscheme Enterprise Partnership. Dr D’Sylva has also been non executive chairman of PharmAust and non executive director of PharmAust subsidiaries Epichem, Pharm-Aust Manufacturing and Mimotopes.